【英語タイトル】Global MRSA Drugs Market 2016-2020

Single User(1名利用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム

About Methicillin-Resistant Staphylococcus aureus (MRSA)
MRSA is an infection of the skin that occurs mostly in hospitals and healthcare facilities. It is treated with commonly-used antibiotics and usually spreads from person to person by direct skin-to-skin contact. Physicians often find MRSA harder to treat than most other strains of Staphylococcus aureus because it is sometimes resistant to commonly-used antibiotics such as methicillin.

Technavio’s analysts forecast the global MRSA drugs market to grow at a CAGR of 1.34% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global MRSA drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent MRSA infections.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global MRSA Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Allergan
• Merck & Co.
• Pfizer
• Theravance Biopharma

[Other prominent vendors]
• Absynth Biologics
• AmpliPhi Biosciences Corporation
• AstraZeneca
• Basilea Pharmaceutica
• Baxter International
• Cellceutix
• Cempra Inc.
• CrystalGenomics
• Debiopharm Group
• Galapagos NV
• KYORIN Pharmaceutical
• Lytix Biopharma
• Melinta Therapeutics
• Nabriva Therapeutics
• NovaDigm Therapeutics
• Paratek Pharmaceuticals
• R-Pharm
• Savara Pharmaceuticals
• Sealife Pharma
• Sequella Inc.
• The Medicines Company
• XBiotech

[Market driver]
• Special regulatory designations
• For a full, detailed list, view our report

[Market challenge]
• Development of drug-resistant strains
• For a full, detailed list, view our report

[Market trend]
• Strategic alliances and M&A
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Key buying criteria

PART 06: Antibacterial: Overview
• Introduction
• General principles for use of antibiotics
• Clinical uses

PART 07: Antimicrobial resistance
• Sources of spread of resistant organisms
• Initiatives to improve antibiotic innovation
• Surveillance systems for antibiotic resistance

PART 08: Legislation relating to antibiotics use in US

PART 09: Pipeline analysis
• Solithromycin
• TD-1792
• Baxdela
• Taksta

PART 10: Market landscape
• Global antibacterial drugs market
• Global MRSA drugs market
• Five forces analysis

PART 11: Market segmentation by drug class
• Tetracycline
• Folate antagonists
• Cephalosporin
• Lipopeptide
• Oxazolidinone
• Lipoglycopeptide

PART 12: Market segmentation by drug origin
• Semisynthetic drugs
• Synthetic drugs

PART 13: Market segmentation by MOA
• Bacteriostatic
• Bactericidal

PART 14: Geographical segmentation
• Global MRSA drugs market by geographical segmentation 2015-2020
• MRSA drugs market in Americas
• MRSA drugs market in EMEA
• MRSA drugs market in APAC

PART 15: Market drivers
• Special regulatory designations
• Increasing prevalence of infections
• Growing awareness of diseases
• Rise in older population

PART 16: Impact of drivers

PART 17: Market challenges
• Development of drug-resistant strains
• Patent expiries and generic penetration
• Decreased investments in research activities

PART 18: Impact of drivers and challenges

PART 19: Market trends
• Strategic alliances and M&A
• Patient assistance programs
• Increased funding for antibiotic research

PART 20: Vendor landscape
• Competitive scenario
• Key vendor profiles
• Allergan
• Merck
• Pfizer
• Theravance
• Other prominent vendors

PART 21: Appendix
• List of abbreviations

PART 22: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Percentage of MRSA infections among Staphylococcus infections in US 2015
Exhibit 03: Percentage of MRSA infections in US based on type 2015
Exhibit 04: Sites of Staphylococcus infections
Exhibit 05: Key buying criteria for MRSA drugs
Exhibit 06: MOA of antibacterial drugs
Exhibit 07: General principles involved in use of antibiotics
Exhibit 08: Causes of AMR
Exhibit 09: Sources of spread of resistant organisms
Exhibit 10: Estimated deaths per year caused by AMR in 2050
Exhibit 11: Initiatives improving antibiotic innovation
Exhibit 12: Surveillance systems of various countries
Exhibit 13: Legislation relating to antibiotics use in US
Exhibit 14: Pipeline portfolio: Global MRSA drugs market
Exhibit 15: Global antibacterial drugs market 2015-2020 ($ billions)
Exhibit 16: Market share of global MRSA drugs in global pharmaceutical market 2015
Exhibit 17: Global MRSA drugs market 2015-2020 ($ billions)
Exhibit 18: Five forces analysis
Exhibit 19: Cephalosporin segmentation by generation of drugs
Exhibit 20: Global MRSA drugs market segmentation based on volume 2015
Exhibit 21: Global MRSA drugs market segmentation by drug origin
Exhibit 22: Global MRSA drugs market segmentation by geography 2015
Exhibit 23: Global MRSA drugs market revenue by geography 2015-2020 ($ millions)
Exhibit 24: Percentage share of global MRSA drugs market by geography 2015-2020
Exhibit 25: MRSA drugs market in Americas 2015-2020 ($ billions)
Exhibit 26: Percentage share of MRSA drugs market in US 2015
Exhibit 27: MRSA drugs market in EMEA 2015-2020 ($ millions)
Exhibit 28: MRSA drugs market in APAC 2015-2020 ($ millions)
Exhibit 29: Global MRSA drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 30: Percentage of MRSA infections 2014
Exhibit 31: Impact of drivers
Exhibit 32: Antibiotic-resistant strains of Staphylococcus according to period of development of resistance
Exhibit 33: Ranking for top ten countries based on antibiotic consumption in livestock 2015
Exhibit 34: Antibacterial drug approvals by FDA and EMA
Exhibit 35: Impact of drivers and challenges
Exhibit 36: Allergan: Key takeaways
Exhibit 37: Merck: YoY revenue and growth rate of Cubicin 2013-2015 ($ billion)
Exhibit 38: Merck: Key takeaways
Exhibit 39: Pfizer: YoY revenue and growth rate of Zyvox 2013-2015 ($ millions)
Exhibit 40: Pfizer: YoY revenue and growth rate of Tygacil 2013-2015 ($ millions)
Exhibit 41: Pfizer: Key takeaways
Exhibit 42: Theravance Biopharma: YoY revenue comparison of Vibativ 2014-2015 ($ millions)
Exhibit 43: Theravance: Key takeaways


Allergan, Merck, Pfizer, Theravance, Absynth Biologics, AmpliPhi Biosciences, AstraZeneca, Basilea Pharmaceutica , Baxter International, Cellceutix, Cempra, CrystalGenomics, Debiopharm, Galapagos NV, GSK, KYORIN Pharmaceutical, Lytix Biopharma, Melinta Therapeutics, Nabriva Therapeutics, NovaDigm Therapeutics, Paratek Pharmaceuticals, R-Pharm, Savara Pharmaceuticals, Sealife Pharma, Sequella, The Medicines Company, XBiotech.





★調査レポート[MRSA(メチシリン耐性黄色ブドウ球菌)薬の世界市場2016-2020] (コード:IRTNTR9071)販売に関する免責事項を必ずご確認ください。